BioSpace News Archive

Alkermes plc announced that it will present new clinical data related to ALKS 4230, its investigational engineered interleukin-2 variant immunotherapy, at the European Society for Medical Oncology Virtual Congress, taking place Sept. 18-21, 2020.

Concert Pharmaceuticals, Inc. announced that it will participate at the following upcoming virtual investor conferences:.

Dr. Vijay Reddy and Simona King, CPA, MBA to Join Executive Team as Chief Research and Development Officer and Chief Financial Officer.

4D Molecular Therapeutics, a clinical-stage leader in the development of precision-guided AAV gene therapy based on directed evolution, announced the appointment of John F. Milligan, Ph.D. as Executive Chairman of the Board of Directors.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced the Company’s CEO Dr. Pnina Fishman will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 2:00 pm ET in Room 6.

PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, announced the appointments of Laurie Stelzer to the Board of Directors as Audit Committee chair, and Robert Ticktin as General Counsel.

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that Executive Directors of the company will present at several reputed international conferences in September, all of them to be held virtually.

VBL Therapeutics (Nasdaq: VBLT) announced today the successful completion of a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company’s development plan for VB-601.

Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced pre-publication of a manuscript titled “Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection.”

Anavex Life Sciences Corp. announced that its President & Chief Executive Officer, Christopher U. Missling, PhD, will present a company update at both the Cantor Fitzgerald Global Healthcare Conference 2020 and the H.C. Wainwright 22nd Annual Global Investment Conference.